

Hypertension in adults (update) Committee meeting

Date: 26/04/2018

Location: NGC Boardroom, Royal College of Physicians, 11 St Andrew's Place, London NW1 4LE

Minutes: Confirmed

NICE National Institute for
Health and Care Excellence

Committee members present:	
Anthony Wierzbicki (Chair)	(Present for notes 1–5)
Liz Clark	(Present for notes 1–4)
Elizabeth Denver	(Present for notes 1–5)
Mark Glover	(Present for notes 1–5)
Judith Magowan	(Present for notes 1–4)
Terry McCormack	(Present for notes 1–5)
Irene McGill	(Present for notes 1–5)
Richard McManus	(Present for notes 1–5)
Lucy Pollock	(Present for notes 1–5)
Mark Shapley	(Present for notes 1–5)

In attendance:		
Rebecca Boffa	Senior Research Fellow, NGC	(Present for notes 1–5)
Serena Carville	Guideline Lead, NGC	(Present for notes 1–5)
Margaret Constanti	Senior Health Economist, NGC	(Present for notes 1–5)
Tamara Diaz	Project Manager, NGC	(Present for notes 1–5)
Christopher Floyd	Clinical Trainee, NGC	(Present for notes 1–5)
Audrius Stonkus	Trainee Research Fellow, NGC	(Present for notes 1–5)

Apologies:	
Alison Warren	Committee member
Bryan Williams	Committee member
Catherine Baden-Daintree	Senior Medical Editor, NICE
Caroline Kier	Guideline Commissioning Manager, NICE

Meredith Faust	Project Manager, NGC
Beatriz Ferrer-Quiles	Information Specialist, NGC
Rafina Yarde	Research Fellow, NGC

1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the seventh meeting on Hypertension in adults. The committee members and attendees introduced themselves.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included treatment initiation, treatment targets and health economic modelling.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was initiation of anti-hypertensive drug treatments and determining optimum blood pressure or cardiovascular risk targets.

The Chair asked everyone to declare verbally any interests that have arisen since the last meeting. No new interests were declared.

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Questions and discussion

- A. Rebecca Boffa, Senior Research Fellow at the NGC, presented the updated clinical evidence for the review question 'At what blood pressure or cardiovascular disease risk threshold should antihypertensive drug treatment be initiated for adults with hypertension?' The committee asked questions about the clinical evidence.
- B. Margaret Constanti, Senior Health Economist at the NGC, presented the health economic evidence for the review question 'At what blood pressure or cardiovascular disease risk threshold should antihypertensive drug treatment be initiated for adults with hypertension?' The committee asked questions about the clinical evidence.
- C. Rebecca Boffa presented the clinical evidence for the review question 'What are the optimum blood pressure or cardiovascular risk targets for adults with treated primary hypertension?' The committee asked questions about the

clinical evidence.

D. Margaret Constanti presented the health economic evidence for the review question 'What are the optimum blood pressure or cardiovascular risk targets for adults with treated primary hypertension?' The committee asked questions about the clinical evidence.

E. Margaret Constanti led a conversation on the development of the health economic model.

5. Any other business

None.

Date of next meeting: 07/06/2018

Location of next meeting: NGC Boardroom, Royal College of Physicians, 11 St Andrew's Place, London NW1 4LE